Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharma giant expects to have 24 to 28 programs in Phase III development by the end of 2009, representing a 50 percent to 70 percent increase, management says during an analyst day March 5. Pain and oncology are key disease areas Pfizer will focus on going forward. Investors, however, were unimpressed with the show